Wipro joins hands with Transcell Oncologics; makes new 52-week high

IT major, Wipro Limited informed the exchanges that it has partnered with Transcell Oncologics in a bid to transform vaccine safety assessment using artificial intelligence.  

The partnership brings together, Transcell’s innovative stem cell technology with the advanced artificial intelligence capabilities of Wipro HOLMES, to improve the safety of global vaccine immunisation programmes.  

At present, vaccine safety assessment includes testing on animals to measure adverse impacts. Wipro believes that by using Wipro HOLMES instead, researchers & biopharmaceutical companies will have a new and fully viable solution that is capable of predicting adverse neurovirulent impacts resulting from vaccinations.   

This will be the first in a number of next-gen solutions that the partnership will bring to the table to determine the safety & efficacy of a wide range of products, ranging from vaccines to prescription medications and cosmetics.   

At 2.42 pm on Thursday, the shares of Wipro Limited were trading at Rs 513.50, up by 4.63 per cent or Rs 22.70 per share, against a 0.42 per cent gain in the benchmark index. The 52-week high of the company is recorded at Rs 514.85 while its 52-week low is Rs 178.20 on BSE.